活動時間：2026年7月17日- 7月18日
活動地點：台南香格里拉飯店B1 (Shangli-La Hotel, Tainan, Taiwan)
活動地址：臺南市東區成大里大學路西段89號
主辦單位：成大醫院外科部、台灣胰臟醫學會、台灣神經內分泌腫瘤學會、台灣胃癌醫學會、台灣消化系外科醫學會
協辦單位：財團法人成杏醫學文教基金會、林炳文教育基金、財團法人徐燕教育基金會
教育學分：台灣外科醫學會、台灣消化系外科醫學會、台灣消化系醫學會、台灣內科醫學會、台灣消化系內視鏡醫學會、中華民國醫用超音波學會、中華民國癌症醫學會、台灣內視鏡外科醫學會
報名連結：請點我
報名截止日：115年7月2日
會議議程：請點我
Day 1 (17/Jul/2026)
| Time | Topic | Speaker | Moderator | |
| 13:00-13:30 | Registration | |||
| 13:30-13:50 |
Opening
|
|||
| Annual Awards for Memory Lecture of Pin-Wen Lin | ||||
| 13:50- 14:30 | The contribution in endoscopic intervention for HBP diseases | Lein-Ray Mo (牟聯瑞) |
Miin-Fu Chen (陳敏夫) Jaw-Town Lin (林肇堂) |
|
| 14:30-14:40 | Discussion | |||
| Investigator Award of Hsu-Yuan Education Foundation | ||||
| 14:40-15:00 | Single-cell RNA sequencing via endoscopic ultrasound-guided fine-needle biopsy for pancreatic tumors uncovered an aggressive subclone with a poor prognosis | Yung-Yeh Su (蘇勇曄) |
Shen-Nien Wang (王森稔) Ming-Huang Chen (陳明晃) |
|
| 15:00-15:20 | Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study in Taiwan | Ping-Jui Su (蘇炳睿) |
||
| 15:20-15:30 | Coffee Break | |||
| 15:30-15:50 | A simple five-factor risk model for predicting new-onset diabetes after distal pancreatectomy | Wei-Hsun Lu (呂維勛) |
Ta-Sen Yeh (葉大森) Li-Tzong Chen (陳立宗) |
|
| 15:50-16:10 | SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217) | Nai-Jung Chiang (姜乃榕) |
||
| Invited talk | ||||
| 16:10-16:40 | The development of ERAS in pancreatic cancer surgery | Hiroki Yamaue (山上裕機) |
Tsann-Long Hwang (黃燦龍) Li-Yuan Bai (白禮源) |
|
| 16:40-17:10 | The tumor-stroma crosstalk in pancreatic cancer: from microenvironmental control to therapeutic innovation | Yi-Ching Wang (王憶卿) |
||
| 17:10-17:40 | The application of immunotherapy in pancreatic cancer. NTUH’s experience | Shih-Hung Yang (楊士弘) |
||
Day 2 (18/Jul/2026)
| Time | Topic | Speaker | Moderator |
| 08:30- 08:50 | Registration | ||
| Invited talk | |||
| 08:50-09:15 | The impact of perioperative treatment for resectable gastric cancer. Japanese point of view | Yukinori Kurokawa (黒川幸典) |
Jen-Shi Chen (陳仁熙) Jaw-Yuan Wan (王照元) Ta-Sen Yeh (葉大森) |
| 09:15-09:40 | The impact of perioperative treatment for resectable gastric cancer. Taiwan’s point of view | I-Shu Chen (陳以書) |
|
| 09:40-09:50 | Discussion | ||
| 09:50-10:10 | Coffee Break | ||
| 10:10-10:35 | Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial | Seiko Hirono (廣野誠子) |
Ming-Huang Chen (陳明晃) Hiroki Yamaue (山上裕機) |
| 10:35-11:00 | Longitudinal dynamic changes of cfDNA levels in blood for prediction of recurrence and survival in pancreatic cancer patients after curative surgery: A prospective cohort study | Chien-Jui Huang (黃千睿) |
|
| 11:00-11:25 | PanMETAI – a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomics | Yu-Ting Chang (張毓廷) |
Chun-Nan Yeh (葉俊男) Li-Yuan Bai (白禮源) |
| 11:25-11:50 | Spatially calibrated liquid biopsy enables early metastatic prediction in pancreatic cancer | Ya-Chin Hou (侯雅琴) |
|
| 12:00-12:30 | Lunch symposium Targeting CLDN18.2: Reshaping the first-line treatment landscape in advanced gastric cancer |
Chih-Chieh Yen (顏志傑) |
De-Chuan Chan (詹德全) Kun-Ming Rau (饒坤銘) |
| 12:30-13:00 | Lunch symposium A phase I/II study of nal-IRI (Onivyde) and carboplatin in patients with advanced or metastatic GEP poorly differentiated NEC |
Nai-Jung Chiang (姜乃榕) |
|
| New development in Pancreatic cancer and Gastric cancer | |||
| 13:10-13:35 | Hierarchical Nodal Burden Defines Risk-Adapted Lymphadenectomy in Early Gastric Cancer | Yi-Fu Chen (陳怡甫) |
Yan-Shen Shan (沈延盛) Chun-Nan Yeh (葉俊男) |
| 13:35-14:00 | The function-preserving surgery for gastric cancer after improving of perioperative surgery | Wen-Liang Fang (方文良) |
|
| 14:00-14:25 | What is the timing for salvage surgery in metastatic gastric cancer. | Cheng-Chan Yu (余政展) |
Ming-Huang Chen (陳明晃) Jun-Te Hsu (徐潤德) |
| 14:25-14:50 | The progress and future development of HIPEC in gastric cancer | Hsin-Hsien Yu (余信賢) |
|
| 14:50-15:10 | Coffee Break | ||
| 15:10-15:35 | Tumor regression grade is a better prognostic marker after resection in pancreatic cancer patients receiving neoadjuvant therapy | Ting-Kai Liao (廖亭凱) |
Shin-E Wang (王心儀) Ying-Jui Chao (趙盈瑞) |
| 15:35-16:00 | Clinical significance of neoadjuvant chemotherapy switch according to biological response in patients with R/BR PDAC | Sohei Satoi (里井壯平) |
|
| 16:00-16:25 | Conversion surgery for initially unresectable locally advanced pancreatic cancer after neoadjuvant chemotherapy/carbon ion radiotherapy | Shin-E Wang (王心儀) |
Ching-Yao Yang (楊卿堯) Nai-Jung Chian (姜乃榕) |
| 16:25-16:50 | Building the First-Line Fortress in Metastatic Pancreatic Cancer | Hsin-Chen Lin (林欣辰) |
|
| 16:50 | Closing: Yan-Shen Shan (沈延盛) | ||